In an effort to address the global health threat of antimicrobial resistance (AMR), Innovate UK, LifeArc, and Medicines Discovery Catapult have jointly launched the PACE (Pathways to Antimicrobial Clinical Efficacy) initiative. With £30m (around €34,5m) in funding, PACE aims to support early-stage innovations aimed at countering AMR.
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.
Bavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.
LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
From its all-time high in August 2021 the largest and most important index for the biotech industry also in Europe (NBI) lost around 25%. After a period of excessive capital inflows, money is much harder to come by these days. The answer can only be more creativity in structuring deals.
Phage therapy specialist Vésale Bioscience gas bageds €1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
With money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies.